세계의 PEG화 단백질 시장은 2024년 18억 달러로 평가되었으며 CAGR 10.9%를 나타내 2034년에는 51억 달러에 이를 것으로 추정되고 있습니다. 이 과정은 단백질과 약물을 폴리에틸렌 글리콜(PEG)로 화학적으로 변형시켜 안정성, 용해성 및 반감기를 향상시키는 것입니다.
표적 치료제의 개발을 위한 연구개발이 강화되는 가운데, PEG화 제제는 약물동태의 개선과 면역원성의 저감에 의해 바람직한 선택지로서 부상하고 있습니다. 암, 자가면역질환, 당뇨병 등, 만성적이고 생명을 위협하는 질환 증가에 의해 보다 안전하고 장시간 작용하는 치료 옵션의 필요성이 현저하게 높아지고 있어 시장의 확대를 더욱 뒷받침하고 있습니다.
| 시장 범위 | |
|---|---|
| 시작 연도 | 2024년 |
| 예측 연도 | 2025-2034년 |
| 시작 금액 | 18억 달러 |
| 예측 금액 | 51억 달러 |
| CAGR | 10.9% |
시장은 소모품과 서비스로 크게 나뉩니다. 소모품 분야는 특수 PEG 유도체 수요가 증가함에 따라 예측 기간 동안 CAGR 10.9%를 나타내 안정한 신장이 예상됩니다. 이 유도체는 단일클론항체와 효소와 같은 PEG화 생물 제제의 성능을 높이는 열쇠가 됩니다. 의약품이 요구되고 있으며 고급 PEG 시약과 폴리머에 대한 의존도가 높아지고 있습니다.
단백질유형별로 보면 인터페론, 콜로니 자극 인자(CSF), 에리스로포이에틴, 항체, 유전자 재조합 인자 VIII, 기타 단백질이 포함되어 있습니다. CSF 부문은 주로 빈혈 및 백혈병과 같은 혈액 질환의 유병률 증가로 인해 2025년부터 2034년까지 연평균 11%의 성장률을 나타낼 것으로 예상됩니다. CSF는 화학요법 및 기타 집중 치료를 받는 환자의 골수 회복을 지원하며 면역 기능을 향상시키는 데 중요한 역할을 합니다.
미국의 PEG화 단백질 시장은 2024년에 7억 3,520만 달러로 평가되었고, 만성 질환의 이환율의 높이와 고도의 헬스케어 인프라의 존재에 의해 대폭적인 성장이 전망되고 있습니다.
시장 주요 기업으로는 Biopharma PEG Scientific, Merck KGaA, Celares, Abcam, Biomatrik, Enzon Pharmaceuticals, JenKem Technology, Aurigene Pharmaceutical Services, Quanta BioDesign, Thermo Fisher Scientific, Laysan Bio, Corporation 등이 있습니다. 이들 기업은 R&D 투자, 포트폴리오 확대, 인수, 공동 전략을 통해 치료 효과와 세계 시장에서의 존재감을 높이고 있습니다.
The Global Pegylated Proteins Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 10.9% to reach USD 5.1 billion by 2034. This notable growth trend reflects the expanding use of protein-based therapeutics in modern medicine. With biologics and biosimilars steadily gaining traction in the global pharmaceutical space, the role of PEGylation technology is becoming increasingly indispensable. This process involves the chemical modification of proteins or drugs with polyethylene glycol (PEG), enhancing their stability, solubility, and half-life. These benefits make PEGylation an essential tool in drug delivery, especially for complex biologics like monoclonal antibodies and recombinant proteins.
As research efforts intensify to develop targeted therapies, PEGylated formulations are emerging as a preferred choice due to their improved pharmacokinetics and reduced immunogenicity. Increasing government support for biologics development, combined with a higher volume of clinical trials in protein therapeutics, continues to push the boundaries of innovation within this sector. The growing incidence of chronic and life-threatening diseases, including cancer, autoimmune disorders, and diabetes, has significantly escalated the need for safer, long-acting treatment options-further reinforcing market expansion.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $1.8 Billion |
| Forecast Value | $5.1 Billion |
| CAGR | 10.9% |
The market is broadly segmented into consumables and services. The consumables segment is poised to witness a steady CAGR of 10.9% during the forecast period as the demand for specialized PEG derivatives rises. These derivatives are key to enhancing the performance of PEGylated biologics, such as monoclonal antibodies and enzymes. With chronic disease rates on the rise globally, the requirement for advanced therapeutics that offer prolonged efficacy is prompting greater reliance on premium-grade PEG reagents and polymers. The emphasis on drug delivery systems that provide better patient compliance and therapeutic efficiency is also bolstering growth within this category.
Based on protein type, the PEGylated proteins market includes interferons, colony-stimulating factors (CSF), erythropoietin, antibodies, recombinant factor VIII, and other protein categories. The CSF segment is projected to grow at a CAGR of 11% from 2025 to 2034, primarily due to the increasing prevalence of hematological disorders such as anemia and leukemia. CSFs play a critical role in supporting bone marrow recovery and enhancing immune function in patients undergoing chemotherapy and other intensive treatments. Their applications are also expanding into newer therapeutic areas like stem cell mobilization and chronic neutropenia.
The U.S. PEGylated Proteins Market reached USD 735.2 million in 2024 and is expected to grow substantially, driven by the high incidence of chronic illnesses and the presence of advanced healthcare infrastructure. A strong concentration of pharmaceutical companies and ongoing innovation in PEGylation technologies are helping the U.S. maintain a dominant market position.
Key players in the global market include Biopharma PEG Scientific, Merck KGaA, Celares, Abcam, Biomatrik, Enzon Pharmaceuticals, JenKem Technology, Aurigene Pharmaceutical Services, Quanta BioDesign, Thermo Fisher Scientific, Laysan Bio, Iris Biotech, Profacgen, Creative PEGworks, and NOF Corporation. These companies are advancing through R&D investments, portfolio expansion, acquisitions, and collaborative strategies to enhance therapeutic efficacy and global market presence.